DuPont de Nemours Inc

Latest Results (28.08.2026):

DuPont de Nemours, Inc. reported results for the first quarter of 2026: net sales of $1.681 billion (up 4% year‑over‑year; organic +2%), GAAP income from continuing operations of $150 million and operating EBITDA of $414 million. GAAP EPS from continuing operations was $0.36 and adjusted EPS was $0.55. Cash provided by operating activities from continuing operations was $232 million, with transaction‑adjusted free cash flow of $147 million. The company completed the Aramids divestiture (April 1, 2026), announced an imminent $275 million accelerated share repurchase and raised its full‑year 2026 guidance.

Key financials

1Q 2026 net sales $1,681M (+4% vs. 1Q25; organic +2%). Operating EBITDA $414M (+15% YoY) with margin 24.6% (+230 bps). GAAP income from continuing operations $150M (vs. $80M) and GAAP EPS $0.36; adjusted EPS $0.55 (up 53% YoY).

Segment performance

Healthcare & Water Technologies: sales $806M (+6%; organic +3%), operating EBITDA $244M and margin 30.3% (+110 bps). Diversified Industrials: sales $875M (+3%; ~flat organic), operating EBITDA $200M and margin 22.9% (+110 bps). Strength in medical packaging/biopharma and industrial/aerospace partially offset by construction weakness and regional logistics issues.

Cash flow and conversion

Operating cash flow from continuing operations $232M; capital expenditures $102M; transaction‑adjusted free cash flow $147M. Transaction‑adjusted free cash flow conversion was 65% (adjusted earnings $226M).

Guidance update

Raised full‑year 2026 guidance. 2Q'26E: net sales ~ $1.8B, operating EBITDA ~ $430M, adjusted EPS ~ $0.59. Full‑year 2026E: net sales $7,155–7,215M, operating EBITDA $1,730–1,760M, adjusted EPS $2.35–2.40. Full‑year outlook assumes ~4% organic growth and ~1% pricing to offset higher input costs.

Portfolio actions & capital allocation

Completed Aramids divestiture on April 1, 2026 for ~ $1.2B cash plus a $300M note and $325M equity stake in New Arclin; results of Aramids are treated as discontinued operations. Announced a $275M accelerated share repurchase to be launched imminently and continues work on a $2B buyback program authorized in November 2025.

Balance sheet snapshot

At March 31, 2026 DuPont reported cash & cash equivalents of $710M, long‑term debt $3,132M, total assets $21,449M and total equity $14,238M. Working capital and liquidity remain supported following the Aramids transaction (completed post‑quarter).

Non‑GAAP context and drivers

Adjusted measures (adjusted EPS, operating EBITDA, transaction‑adjusted free cash flow) exclude items like amortization, separation‑related costs, Future Reimbursable Indirect Costs and Corporate DDOB remediation. Management cites organic growth, favorable mix, productivity and lower interest expense as key drivers of improved adjusted results.